Physician profile
Asher A Chanan Khan
NPI 1194722462
$108,794.80
in general payments reported to CMS, 2019-2025
23 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,205 · 2020: $2,800 · 2021: $94K · 2022: $8,715 · 2023: $861 · 2024: $96.44 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $842 · Food and Beverage: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $842.00 |
| Food and Beverage | $258.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene, Ltd. | $82,608.50 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $15,627.32 | 2021-2022 | |
| Astrazeneca Uk Limited | $4,452.50 | 2019-2021 | |
| Beigene USA, INC. | $2,299.00 | 2020-2024 | Brukinsa |
| Genentech USA, INC. | $1,650.00 | 2022 | |
| Adaptive Biotechnologies Corporation | $1,500.00 | 2020 | |
| Janssen Global Services, LLC | $310.00 | 2021 | |
| Beone Medicines USA, INC. | $143.13 | 2025 | Brukinsa |
| Teva Pharmaceuticals USA, INC. | $121.87 | 2019 | |
| Tg Therapeutics, INC. | $23.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.54 | 2023 | Iclusig |
| Janssen Research & Development, LLC | $14.64 | 2019 | |
| Janssen Scientific Affairs, LLC | $13.39 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asher Chanan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.